Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 323 clinical trials
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

renal cell carcinoma (RCC).

progressive disease
tyrosine
measurable disease
vegf
growth factor
  • 27 views
  • 21 May, 2021
  • 45 locations
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with

cancer
advanced soft tissue sarcoma
platelet count
gemcitabine
doxorubicin
  • 13 views
  • 07 Nov, 2020
  • 1 location
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

advanced renal cell carcinoma
tyrosine
everolimus
vegf
growth factor
  • 168 views
  • 16 Jun, 2021
  • 178 locations
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The

tyrosine
measurable disease
vegf
growth factor
kinase inhibitor
  • 0 views
  • 20 May, 2021
  • 38 locations
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior

lenvatinib
measurable disease
clear cell renal cell carcinoma
programmed cell death 1 ligand 1
karnofsky performance status
  • 0 views
  • 17 Jun, 2021
  • 32 locations
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy

lenvatinib
pembrolizumab
systemic therapy
carcinoma
major surgery
  • 0 views
  • 16 Jun, 2021
  • 19 locations
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy

lenvatinib
tyrosine
vegf
growth factor
major surgery
  • 0 views
  • 16 Jun, 2021
  • 18 locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to

lenvatinib
pembrolizumab
systemic therapy
carcinoma
clear cell renal cell carcinoma
  • 0 views
  • 16 Jun, 2021
  • 22 locations
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.

pet scan
carcinoma
clear cell renal cell carcinoma
nephrectomy
  • 21 views
  • 12 May, 2021
  • 40 locations
Renal Adjuvant MultiPle Arm Randomised Trial

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients

cancer
platelet count
corticosteroids
tremelimumab
nephrectomy
  • 60 views
  • 25 Jan, 2021
  • 35 locations